• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Vantas (histrelin acetate) Subcutaneous Implant

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

July 2014

Summary View

WARNINGS AND PRECAUTIONS

Effect on QT/QTc Interval
  • Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes. 

 

April 2013

Summary View

 

ADVERSE REACTIONS

Post-marketing
  • Nervous System Disorders: Convulsions

 

February

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience
  • Drug-Induced Liver Injury: Severe liver injury has been reported in association with Vantas. The toxicity was reversible with the removal of the Vantus implant.

 

January 

Summary View

 

PRECAUTIONS

Hyperglycemia and diabetes
  • Hyperglycemia and an increased risk of developing diabetes have been reported in men patients receiving GnRH agonists. Hyperglycemia may represent development of diabetes mellitus or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes.
Cardiovascular disease
  • Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists in men. The risk =appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.